This is the authors' abstract. We don't add key points for this paper.
Nonalcoholic fatty liver disease (NAFLD) is considered as a liver manifestation of metabolic disorders. Previous studies indicate that the renin-angiotensin system (RAS) plays a complex role in NAFLD. As the only precursor of the RAS, decreased angiotensinogen (AGT) profoundly impacts RAS bioactivity. Here, we investigated the role of hepatocyte-derived AGT in liver steatosis. AGT floxed mice (hepAGT +/+ ) and hepatocyte-specific AGT-deficient mice (hepAGT −/− ) were fed a Western diet and a normal laboratory diet for 12 weeks, respectively. Compared with hepAGT +/+ mice, Western diet-fed hepAGT −/− mice gained less body weight with improved insulin sensitivity. The attenuated severity of liver steatosis in hepAGT −/− mice was evidenced by histologic changes and reduced intrahepatic triglycerides. The abundance of SREBP1 and its downstream molecules, acetyl-CoA carboxylase and FASN, was suppressed in hepAGT −/− mice. Furthermore, serum derived from hepAGT +/+ mice stimulated hepatocyte SREBP1 expression, which could be diminished by protein kinase B (Akt)/mammalian target of rapamycin (mTOR) inhibition in vitro. Administration of losartan did not affect diet-induced body weight gain, liver steatosis severity, and hepatic p-Akt, p-mTOR, and SREBP1 protein abundance in hepAGT +/+ mice. These data suggest that attenuation of Western diet-induced liver steatosis in hepAGT −/− mice is associated with the alternation of the Akt/mTOR/SREBP-1c pathway.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Tao et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: